PEGylation of interleukin-10 for the mitigation of enhanced pain states

Journal of Biomedical Materials Research - Part A

Volumn 93, Issue 3, 2010, Pages 1169-1179

  Soderquist, Ryan G ^a   Milligan, Erin D ^b   Harrison, Jacqueline A ^c   Chavez, Raymond A ^d   Johnson, Kirk W ^d   Watkins, Linda R ^c   Mahoney, Melissa J ^a  

^a UCB 450   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Avigen Inc   (United States)

Author keywords

Glia; Interleukin 10; Intrathecal delivery; Neuropathic pain; Pegylation

Indexed keywords

ANIMAL MODEL; ANTI-INFLAMMATORIES; BIOLOGICAL ACTIVITIES; CEREBRO SPINAL FLUIDS; CONCENTRATION OF; CYTOKINES; IN-VITRO; IN-VIVO; INTERLEUKIN-10; INTRATHECAL; NEUROPATHIC PAIN; PEGYLATION; PROTEIN LEVEL; REDUCTIVE AMINATION;

BIOACTIVITY; BODY FLUIDS; BRAIN; POLYETHYLENE OXIDES;

POLYETHYLENE GLYCOLS;

MACROGOL 20000; RECOMBINANT INTERLEUKIN 10;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULE; NEUROPATHIC PAIN; NONHUMAN; RAT;

ANIMALS; BEHAVIOR, ANIMAL; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; INJECTIONS, SPINAL; INTERLEUKIN-10; MICE; PAIN; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 77950687024     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32611     Document Type: Article

References (60)

1. Miller G. The dark side of glia. Science 2005;308:778-781.
2. Suter MR, Wen YR, Decosterd I, Ji RR. Do glial cells control pain? Neuron Glia Biol 2007;3:255-268.
3. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008;60:297-307.
4. Milligan ED, O'connor KA, Nguyen K, Armstrong CB, Twining C, Gaykema RPA, Holguin A, Martin D, Maier SF, Watkins LR. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 2001;21:2808-2819.
5. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain 2000;4:247-257.
6. Oka T, Aou SJ, Hori T. Intracerebroventricular injection of interluekin-1-beta enhances nociceptive neuronal responses of the trigeminal nucleus caudalis in rats. Brain Res 1994;656:236-244. (Pubitemid 24277107)
7. Moore KW, Malefyt RD, Coffman RL, O'garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765.
8. Backonja MM, Coe CL, Muller DA, Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008;195:157-163.
9. Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T. IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta 1 and blood-brain barrier function. J Neuroimmunol 1999;101:211-221. (Pubitemid 29516464)
10. Plunkett JA, Yu CG, Easton JM, Bethea JR, Yezierski RP. Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp Neurol 2001;168:144-154. (Pubitemid 32195266)
11. Ledeboer A, Wierinckx A, Bol J, Floris S, De Lavalette CR, De Vries HE, Van Den Berg TK, Dijkstra CD, Tilders FJH, Van Dam AM. Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J Neuroimmunol 2003;136:94-103. (Pubitemid 36298848)
12. Kastin AJ, Akerstrom V, Pan WH. Interleukin-10 as a CNS therapeutic: The obstacle of the blood-brain/blood-spinal cord barrier. Mol Brain Res 2003;114:168-171. (Pubitemid 36773559)
13. Milligan ED, Langer SJ, Sloane EM, He L, Wieseler-Frank J, O'connor K, Martin D, Forsayeth JR, Maier SF, Johnson K, Chavez RA, Leinwand LA, Watkins LR. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005;21:2136-2148.
14. Milligan ED, Sloane EM, Langer SJ, Cruz PE, Chacur M, Spataro L, Wieseler-Frank J, Hammack SE, Maier SF, Flotte TR, Forsayeth JR, Leinwand LA, Chavez R, Watkins LR. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 2005;1:1-9.
15. Milligan ED, Sloane EM, Langer SJ, Hughes TS, Jekich BM, Frank MG, Mahoney JH, Levkoff LH, Maier SF, Cruz PE, Flotte TR, Johnson KW, Mahoney MM, Chavez RA, Leinwand LA, Watkins LR. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain 2006;126:294-308.
16. Milligan ED, Soderquist RG, Malone SM, Mahoney JH, Hughes TS, Langer SJ, Sloane EM, Maier SF, Leinwand LA, Watkins LR, Mahoney MJ. Intrathecal polymer-based interleukin-10 gene delivery for neuropathic pain. Neuron Glia Biol 2006;2:293-308.
17. Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002;54:459-476.
18. Bailon P, Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm Sci Technol Today 1998;1:352-356.
19. Hinds KD, Campbell KM, Holland KM, Lewis DH, Piche CA, Schmidt PG. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J Control Release 2005;104:447-460.
20. Pean JM, Boury F, Venier-Julienne MC, Menei P, Proust JE, Benoit JP. Why does PEG 400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm Res 1999;16:1294-1299.
21. Diwan M, Park TG. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J Control Release 2001;73:233-244. (Pubitemid 32539252)
22. Lee H, Jang IH, Ryu SH, Park TG. N-terminal site-specific mono-PEGylation of epidermal growth factor. Pharm Res 2003;20:818-825. (Pubitemid 36515317)
23. Soderquist RG, Milligan ED, Sloane EM, Harrison JA, Douvas KK, Potter JM, Hughes TS, Chavez RA, Johnson K, Watkins LR, Mahoney MJ. PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A 2009;91:719-729.
24. Dhalluin C, Ross A, Leuthold LA, Foser S, Gsell B, Muller F, Senn H. Structural and biophysical characterization of the 40 kDa PEG-interferon- alpha(2a) and its individual positional isomers. Bioconjug Chem 2005;16:504-517. (Pubitemid 40696041)
25. Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:3S-8S. (Pubitemid 36904012)
26. Veronese FM. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 2001;22:405-417.
27. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
28. Milligan ED, Mehmert KK, Hinde JL, Harvey LO, Martin D, Tracey KJ, Maier SF, Watkins LR. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res 2000;861:105-116. (Pubitemid 30177288)
29. Pletnev S, Magracheva E, Wlodawer A, Zdanov A. A model of the ternary complex of interleukin-10 with its soluble receptors. BMC Struct Biol 2005;5.
30. Zhou X. Boosting Interleukin-10 Production. Current Drug Targets, Immune, Endocrine and Metabolic Disorders. Hilversum, Netherlands: Bentham Science Publishers; 2005. p 465-475.
31. Walter MR, Nagabhushan TL. Crystal-structure of interleukin-10 reveals an interferon gamma-like fold. Biochemistry 1995;34:12118-12125.
32. Zdanov A. Structural features of the interleukin-10 family of cytokines. Curr Pharm Des 2004;10:3873-3884. (Pubitemid 39591904)
33. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima F, Chang S, Chu H, Mukku V, Canova-Davis E, Somer T, Cronin M, Winkler M, Wells JA. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem 1996;271:21969-21977. (Pubitemid 26303822)
34. Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. Modulating pharmacokinetics of an anti-interleukin-8 F(ab′)(2) by amine-specific PEGylation with preserved bioactivity. Int J Pharmaceutics 2000;198:83-95.
35. Paulson PE, Casey KL, Morrow TJ. Long-term changes in behavior and regional cerebral blood flow associated with painful peripheral mononeuropathy in the rat. Pain 2002;95:31-40.
36. Paulson PE, Morrow TJ, Casey KL. Bilateral behavioral and regional cerebral blood flow changes during painful peripheral mononeuropathy in the rat. Pain 2000;84:233-245.
37. Gasche C, Grundtner P, Zwirn P, Reinisch W, Shaw SH, Zdanov A, Sarma U, Williams LM, Foxwell BM, Gangl A. Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol 2003;170:5578-5582. (Pubitemid 36617847)
38. Opal SM, Depalo VA. Anti-inflammatory cytokines. Chest 2000;117:1162-1172.
39. Heyen JRR, Ye SM, Finck BN, Johnson RW. Interleukin (IL)-10 inhibits IL-6 production in microglia by preventing activation of NF-kappa B. Mol Brain Res 2000;77:138-147.
40. Ledeboer A, Jekich BM, Sloane EM, Mahoney JH, Langer SJ, Milligan ED, Martin D, Maier SF, Johnson KW, Leinwand LA, Chavez RA, Watkins LR. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 2007;21:686-698. (Pubitemid 46829773)
41. Esposito P, Barbero L, Caccia P, Caliceti P, D'antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogs. Adv Drug Deliv Rev 2003;55:1279-1291.
42. Basu A, Yang K, Wang ML, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu DC, Zhang ZF, Hua J, Hsieh MC, Zhou J, Petti G, Li XG, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation. Bioconjug Chem 2006;17:618-630. (Pubitemid 43794371)
43. Edwards CK, Martin SW, Seely J, Kinstler O, Buckel S, Bendele AM, Cosenza ME, Feige U, Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev 2003;55:1315-1336. (Pubitemid 37464564)
44. Na DH, Lee KC, Deluca PP. PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm Res 2005;22:743-749.
45. Lee H, Park TG. Preparation and characterization of mono-PEGylated epidermal growth factor: Evaluation of in vitro biologic activity. Pharm Res 2002;19:845-851. (Pubitemid 34686745)
46. Arduini RM, Li ZF, Rapoza A, Gronke R, Hess DM, Wen DY, Miatkowski K, Coots C, Kaffashan A, Viseux N, Delaney J, Domon B, Young CN, Boynton R, Chen LL, Chen LQ, Betzenhauser M, Miller S, Gill A, Pepinsky RB, Hochman PS, Baker DP. Expression, purification, and characterization of rat interferon-beta, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters. Protein Expr Purif 2004;34:229-242. (Pubitemid 38390571)
47. Gesser B, Leffers H, Jinquan T, Vestergaard C, Kirstein N, Sindet-Pedersen S, Jensen SL, Thestrup-Pedersen K, Larsen CG. Identification of functional domains on human interleukin 10. Proc Natl Acad Sci USA 1997;94:14620-14625. (Pubitemid 28041423)
48. Zdanov A, Schalkhihi C, Wlodawer A. Crystal structure of human interleukin-10 at 1.6 angstrom resolution and a model of a complex with its soluble receptor. Protein Sci 1996;5:1955-1962. (Pubitemid 126772951)
49. Greenwald RB, Yang K, Zhao H, Conover CD, Lee S, Filpula D. Controlled release of proteins from their poly(ethylene glycol) conjugates: Drug delivery systems employing 1,6-elimination. Bioconjug Chem 2003;14:395-403. (Pubitemid 36348663)
50. Scarisbrick IA, Towner MD, Isackson PJ. Nervous system-specific expression of a novel serine protease: Regulation in the adult rat spinal cord by excitotoxic injury. J Neurosci 1997;17:8156-8168.
51. Mitsui S, Okui A, Uemura H, Mizuno T, Yamada T, Yamamura Y, Yamaguchi N. Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease. In: Delatorre JC, Kalaria R, Nakajima K, Nagata K, editors. New York: Acad Sciences; 2002. p 216-223.
52. Harris MJ, Martin NE, Modi M. Pegylation: A novel process for modifying pharmacokinetics. Clin Pharm 2001;40:539-551. (Pubitemid 32738660)
53. Sakane T, Pardridge WM. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm Res 1997;14:1085-1091.
54. Rosenblum LY, Johnson RC, Schmahai TJ. Preclinical safety evaluation of recombinant human interleukin-10. Regul Toxicol Pharmacol 2002;35:56-71. (Pubitemid 34174541)
55. Johnston IN, Milligan ED, Wieseler-Frank J, Frank MG, Zapata V, Campisi J, Langer S, Martin D, Green P, Fleshner M, Leinwand L, Maier SF, Watkins LR. A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 2004;24:7353-7365. (Pubitemid 39100704)
56. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL. Cytokine involvement in dynorphin-induced allodynia. Pain 2000;84:159-167.
57. Yu CG, Fairbanks CA, Wilcox GL, Yezierski RP. Effects of agmatine, interleukin-10, and cyclosporin on spontaneous pain behavior after excitotoxic spinal cord injury in rats. J Pain 2003;4:129-140.
58. Chacur M, Milligan ED, Sloan EM, Wieseler-Frank J, Barrientos RM, Martin D, Poole S, Lomonte B, Gutierrez JM, Maier SF, Cury Y, Watkins LR. Snake venom phospholipase A2s (Asp49 and Lys49) induce mechanical allodynia upon peri-sciatic administration: Involvement of spinal cord glia, proinflammatory cytokines and nitric oxide. Pain 2004;108:180-191. (Pubitemid 38251688)
59. Abraham KE, Mcmillen D, Brewer KL. The effects of endogenous interleukin-10 on gray matter damage and the development of pain behaviors following excitotoxic spinal cord injury in the mouse. Neuroscience 2004;124:945-952. (Pubitemid 38328783)
60. Daly SM, Przybycien TM, Tilton RD. Adsorption of poly(ethylene glycol)-modified ribonuclease A to a poly(lactide-coglycolide) surface. Biotechnol Bioeng 2005;90:856-868.